Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH)
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Jiménez, César
- dc.contributor.author Garcia-Retortillo, Montserrat
- dc.contributor.author Cirera Lorenzo, Isabel
- dc.contributor.author Cañete Hidalgo, Nuria
- dc.contributor.author Vargas, Víctor
- dc.date.accessioned 2022-10-07T06:25:34Z
- dc.date.available 2022-10-07T06:25:34Z
- dc.date.issued 2022
- dc.description.abstract Background & aims: Alcoholic hepatitis (AH) is associated with a high incidence of infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We aimed to study whether the administration of rifaximin as an adjuvant treatment to corticosteroids decreases the number of bacterial infections at 90 days in patients with severe AH compared to a control cohort. Methods: This was a multicentre, open, comparative pilot study of the addition of rifaximin (1200 mg/day/90 days) to the standard treatment for severe AH. The results were compared with a carefully matched historical cohort of patients treated with standard therapy and matching by age and model of end-stage liver disease (MELD). We evaluated bacterial infections, liver-related complications, mortality and liver function tests after 90 days. Results: Twenty-one and 42 patients were included in the rifaximin and control groups respectively. No significant baseline differences were found between groups. The mean number of infections per patient was 0.29 and 0.62 in the rifaximin and control groups, respectively (p = .049), with a lower incidence of acute-on-chronic liver failure (ACLF) linked to infections within the treatment group. Liver-related complications were lower within the rifaximin group (0.43 vs. 1.26 complications/patient respectively) (p = .01). Mortality was lower in the treated versus the control groups (14.2% vs. 30.9, p = .15) without significant differences. No serious adverse events were associated with rifaximin treatment. Conclusions: Rifaximin is safe in severe AH with a significant reduction in clinical complications. A lower number of infections and a trend towards a lower ACLF and mortality favours its use in these patients.
- dc.format.mimetype application/pdf
- dc.identifier.citation Jiménez C, Ventura-Cots M, Sala M, Calafat M, Garcia-Retortillo M, Cirera I et al. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH). Liver Int. 2022 May;42(5):1109-20. DOI: 10.1111/liv.15207
- dc.identifier.doi http://dx.doi.org/10.1111/liv.15207
- dc.identifier.issn 1478-3223
- dc.identifier.uri http://hdl.handle.net/10230/54305
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Liver Int. 2022 May;42(5):1109-20
- dc.rights © 2022 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Acute-on-chronic liver failure
- dc.subject.keyword Alcohol-related liver disease
- dc.subject.keyword Bacterial infection
- dc.subject.keyword Cirrhosis
- dc.subject.keyword Rifaximin
- dc.subject.keyword Severe alcoholic hepatitis
- dc.title Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH)
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion